This is one half of a proposed multicenter study. The specific goals of this proposed are: a) to compare the effects of chlorimipramine (CMI), behavior therapy (BT), CMI+BT, and pill placebo for symptoms of obsessive-compulsive disorder (OCD); and b) to compare the relapse rates for the different groups after discontinuation of treatment. This proposal is a collaboration between pharmacologically and behaviorally oriented research programs. Each center will enter 76 patients, randomized in a 12-week trial with the following groups: CMI alone, BT alone, CMI + BT, and placebo pill. After week 12, responders will be tapered and/or discontinued from treatments and followed blind to former treatment status for 12 weeks. Medication will be tapered within three weeks.
| Simpson, Helen Blair; Foa, Edna B; Liebowitz, Michael R et al. (2013) Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry 70:1190-9 |
| Huppert, Jonathan D; Simpson, H Blair; Nissenson, Kore J et al. (2009) Quality of life and functional impairment in obsessive-compulsive disorder: a comparison of patients with and without comorbidity, patients in remission, and healthy controls. Depress Anxiety 26:39-45 |
